文献速递哮喘

重度哮喘生物制剂治疗后的临床缓解:系统综述与荟萃分析

Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis.
PubMed 文献 · Lancet Respir Med · 2024-11-14

该系统综述与荟萃分析纳入25项研究,评估重度哮喘患者接受生物制剂后临床缓解的获得率、定义及影响因素。三组分定义下汇总缓解率为38%(95%CI 29-47),四组分定义下为30%(27-34)。较差的FEV1、更重的哮喘症状、更长的病程、口服激素维持治疗及合并抑郁或肥胖与更低的缓解率相关。

要点

  • 三组分定义下重度哮喘生物制剂治疗后临床缓解率为38%(95%CI 29-47)。
  • 四组分定义下临床缓解率为30%(95%CI 27-34)。
  • 更长病程、更重症状、口服激素及合并抑郁或肥胖是缓解的重要障碍。

核心结论

  • 临床缓解是少数接受生物制剂治疗的重度哮喘患者可达到的目标。
  • 临床缓解定义在研究间差异显著,并实质性影响缓解率,亟需共识驱动的统一定义。
  • 更长病程、更高哮喘严重度及合并症是临床缓解的重要障碍,提示早期有效干预和更广泛的可治疗特征策略可能改善结局。

研究设计与样本

  • 系统综述与荟萃分析,检索Web of Science、Embase和MEDLINE从建库至2024年6月13日的文献。
  • 纳入25项研究,报告28个临床缓解获得率分析,无研究设计限制。
  • 采用DerSimonian-Laird随机效应模型进行荟萃分析,异质性用I2统计量评估,研究注册于PROSPERO(CRD42024507233)。

主要发现

  • 共识别68种临床缓解定义,其中48种为独特定义,研究间对定义尤其症状和肺功能方面共识甚少。
  • 三组分定义下汇总缓解率为38%(95% CI 29-47;I2=93%),四组分定义下为30%(95% CI 27-34;I2=83%)。

关键数值与推荐

  • 三组分临床缓解定义包括口服激素维持使用、急性发作和哮喘症状负担。
  • 四组分定义在三组分基础上增加肺功能。
  • 8个分析采用三组分定义,25个分析采用四组分定义。

临床怎么用

  • 临床中应认识到生物制剂治疗后仅约三成至四成重度哮喘患者达到临床缓解。
  • 评估缓解时需关注FEV1、症状负担、病程、口服激素使用及合并抑郁或肥胖等可干预因素。
  • 对重度哮喘应尽早考虑有效治疗,并采用更广泛的可治疗特征方法管理合并症。

局限性

  • 研究间临床缓解定义异质性高(I2最高达93%),影响汇总结果的解释。
  • 纳入研究设计不限,可能存在方法学差异。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical remission has emerged as an important treatment goal in severe asthma; however, studies have reported variable attainment due to differences in study populations, definitions, and methods. We aimed to perform a systematic review and meta-analysis of clinical remission attainment, definitions, and correlates among patients with severe asthma who have been treated with biologics. METHODS: In this systematic review and meta-analysis, we searched Web of Science, Embase, and MEDLINE, using the keywords "asthma" and "remission", for studies published between database inception and June 13, 2024, that reported clinical remission among patients with severe asthma treated with biologics. Studies were eligible for inclusion in both the systematic review and meta-analysis if they were published in English language peer-reviewed journals and reported rates of clinical remission for patients treated with biologics for severe asthma. There were no limitations by study design. Two reviewers independently screened identified papers (AS and CR), with disagreements resolved through consensus or referral to a third reviewer (JB). Study-level data on study characteristics, clinical remission definitions, clinical remission attainment, and the potential correlates of clinical remission were extracted independently by two reviewers (AS and CR) using Covidence. We defined a three-component definition of clinical remission, which included use of maintenance oral corticosteroids, exacerbations, and asthma symptom burden, and a four-component definition, which additionally included lung function. We meta-analysed the rate of attainment of clinical remission and assessed the correlates of clinical remission using DerSimonian-Laird random-effects models. Statistical heterogeneity was assessed using the I2 statistic. This study was registered with PROSPERO, CRD42024507233. FINDINGS: Our search identified 3014 potentially eligible studies, of which 1812 were screened. 25 studies were included, which reported 28 analyses of clinical remission attainment. 68 definitions of clinical remission were identified, of which 48 were unique. Little consensus was found between studies in terms of the clinical remission definition, particularly for symptoms and lung function. Eight analyses used the three-component definition of clinical remission and 25 used the four-component definition. The pooled proportion of patients who attained clinical remission was 38% (95% CI 29-47; I2=93%) for the three-component definition and 30% (27-34; I2=83%) for the four-component definition. Several pulmonary factors were associated with lower clinical remission rates, including worse FEV1 (odds ratio 0·09 [95% CI 0·01-0·92]; I2=87%), worse asthma symptoms (0·23 [0·17-0·33]; I2=0%), longer asthma duration (0·49 [0·32-0·76]; I2=22%), and use of maintenance oral corticosteroids (0·57 [0·40-0·79]; I2=49%). The presence of comorbidities, in particular depression (0·38 [0·23-0·61]; I2=6%) and obesity (0·41 [0·31-0·54]; I2=0%), were important non-pulmonary barriers to clinical remission. INTERPRETATION: Clinical remission is an achievable goal for a minority of patients with severe asthma treated with biologics. Definitions of clinical remission varied substantially between studies, and materially affected attainment, suggesting an urgent need for further consensus-driven definitions. Longer disease duration, higher asthma severity, and the presence of comorbidities were identified as important barriers to clinical remission, suggesting that earlier intervention with effective treatments and a broader treatable traits approach might improve outcomes. FUNDING: Health Data Research UK, Inflammation and Immunity driver project.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Shackleford A, Heaney LG, Redmond C, et al. Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis. Lancet Respir Med. 2024. PMID: 39549709. doi:10.1016/S2213-2600(24)00293-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。